Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors

Molecular Oncology

Volumn 2, Issue 2, 2008, Pages 161-163

  McAuliffe, John C ^a,b   Wang, Wei Lein ^a   Pavan, Giovanni M ^c   Pricl, Sabrina ^c   Yang, Dan ^a   Chen, Su S ^a   Lazar, Alexander J F ^a   Pollock, Raphael E ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

GIST; Kit; Mutations; Sensitivity

Indexed keywords

IMATINIB; STEM CELL FACTOR;

CANCER GENETICS; CANCER RESISTANCE; CANCER SURGERY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LETTER; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

DRUG RESISTANCE, NEOPLASM; EXONS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MUTATION, MISSENSE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 46849106059     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.05.002     Document Type: Letter

References (6)

1. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Research 64 (2004) 5913-5919
2. Desai J., Shankar S., Heinrich M.C., et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clinical Cancer Research 13 (2007) 5398-5405
3. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology 24 (2006) 4764-4774
4. Lasota J., Corless C.L., Heinrich M.C., et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Modern Pathology (2008)
5. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. Journal of Clinical Oncology 20 (2002) 3898-3905
6. Tamborini E., Pricl S., Negri T., et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 25 (2006) 6140-6146